Results from a recent clinical trial showed that both agents can cause transient myelosuppression, but the incidence was not high enough to warrant dose modification. Myelosuppression appeared invariably reversible after discontinuation of treatment. Because severe neutropenia is associated with increased mortality, decitabine should be used carefully in elderly patients and cedazuridine must be used cautiously in women.
Knowledge about the etiology of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) is limited primarily because little research has been done. This lack of knowledge limits our ability to develop effective prevention strategies. Cancer Genetics Core investigators are combining their expertise in genetics, physiology and molecular biology to identify genetic predispositions and the best way to prevent prostate cancer.\nResearch in this area will lead to more effective treatment options and help reduce the number of unnecessary prostate biopsies and surgeries.
Current guidelines recommend radical prostatectomy with intraoperative frozen section analysis for clinically organ confined localised prostate cancer. In accordance with these recommendations, low risk prostate cancers are treated surgically without the use of adjuvant therapy. However, it is clear that some prostate cancers do not fit into this category. They have either metastasized locally or systemically and therefore warrant more aggressive treatments.
Recent findings does not support an association between smoking and prostate cancer incidence. The higher prostate cancer incidence among the black cohort may be explained by earlier age at onset of smoking and longer duration of smoking. However, smoking was strongly associated with a lower age at first diagnosis of prostate cancer. Furthermore, our findings suggest that African Americans are more likely than whites to be diagnosed with prostate cancer late in life.
Decitabine and cedazuridine are both active agents in determining prognosis in patients with advanced gastrointestinal stromal tumours. Data from a recent study suggests that further use of these agents in the treatment of GISTs should be explored in future trials.
An increasing proportion of men with PC are diagnosed at an earlier stage. This may reflect greater awareness of symptoms by clinicians. The exact cause remains unknown. Results from a recent clinical trial suggest that the increase in PC incidence can be attributed to changes in diagnostic practices rather than changes in exposure to carcinogens; however, further studies are needed to confirm our results and to identify other possible causes.
• The signs and symptoms of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) vary according to the stage and grade of cancer, but can be broadly categorized into four groups: • The early signs and symptoms include lower urinary tract symptoms such as frequency, urgency, and urge incontinence; the late signs and symptoms are skeletal metastases, which may occur within 12 months after the initial pathology report; • The biochemical features of prostate cancer are listed below; • • The pathologic features are listed below.
Decitabine and cedazuridine are well tolerated at the doses studied. These agents have significant activity against pediatric leukemia. Decitabine was also found to be active In a recent study with only mild side effects. Cedazuridine did not show any active anti-leukemia effects but it produced severe myelosuppression in most patients.
Breast cancer affects about 1,200,000 women and colon cancer affects about 700,000 women each year in the United States; however, prostate cancer affects only about 100,000 men during their lifetime. This means that less than 10% of all cancers are related to sex. It also means that more than 20 million men over the age of 50 years will be affected by prostate cancer at some time in their lives.
Although many treatment options are available for prostate cancer, some treatment options can cause serious side effects. Physicians need to be aware of common treatment options for prostate cancer when counseling patients.
In spite of its effectiveness as an anti-cancer agent, decitabine behaved like conventional chemotherapy in terms of toxicity, side effects and response rate. Cedazuridine was better tolerated but still less effective than decitabine. Decitabine had better efficacy when compared with cedazuridine for patients who were previously treated with bortezomib. This suggests that these drugs could be combined in the treatment of relapsed patients.